Free Newsletter
Bavarian Nordic reviewing partners for cancer vax
Bavarian Nordic says it has gathered between five and nine term sheets from potential partners for its experimental prostate cancer vaccine. The company's business development chief, Juergen Langhaerig, told a conference that the mix of international companies included some of the "largest companies in the world, the top 10, and some are mid-sized, fast-growing companies." Story
Comments
Post new comment
Paid Research Reports
- Russia Pharmaceutical Market Overview - Pharma companies target Russia despite the challenges it presents
- Stakeholder Insight: Breast Cancer (Hormone Receptor-Negative) - Triple-negative breast cancer offers a significant opportunity
- Infectious Diseases Vaccine Market Overview
- Commercial Insight: Top 20 Cancer Therapy Brands
- Strategies for Managing Pharmaceutical Workforce and Site Reductions: Analysis of legal, productivity, and quality control issue
- The Top 10 Biotechnology Companies: Positioning, performance and SWOT analyses
More Research Reports >>
SHARE
WITH: